Table 3 Change over 36 weeks in patient-reported outcomes (ITT population)

Endpoint

Placebo

(n = 145)

150 mg Q

(n = 145)

450 mg Q

(n = 145)

300 mg M

(n = 143)

Mean change in total asthma symptoms score (mTASS)

−1.5

0.1, p = 0.58

0.1, p = 0.55

−0.1, p = 0.51

Mean change in daytime asthma symptoms score (mTASS)

−0.7

0.1, p = 0.55

0, p = 0.70

0, p = 0.69

Mean change in ACQ-5 score

−1.2

0, p = 0.86

0, p = 0.83

−0.1, p = 0.52

Mean change in AQLQ(S) score

1.1

−0.1, p = 0.67

0.1, p = 0.73

0.3, p = 0.05

Mean change in RQLQ(S) score

−0.6

0, p = 0.96

−0.1, p = 0.35

−0.3, p = 0.04

Proportion of patients at Week 36 with no nighttime awakenings in the previous week

0.43

−0.07, p = 0.21

−0.02, p = 0.69

0, p = 0.97

Proportion of patients at Week 36 with ≤2 days of rescue medication use in the previous week

0.42

0.01, p = 0.88

0.01, p = 0.86

0.06, p = 0.33